Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data demonstrates several notable trends in profitability and efficiency metrics over the five-year period.
- Gross Profit Margin
- The gross profit margin shows a gradual decline from 88.14% in 2020 to 86.11% in 2024. Although the margin remains high, this consistent decrease suggests rising costs of goods sold or downward pressure on product pricing over time.
- Operating Profit Margin
- This metric exhibits considerable volatility. After a significant drop from 46.03% in 2020 to 36.73% in 2021, it rebounded sharply to 48.23% in 2022. However, it fell again to 38.83% in 2023 and turned negative to -2.11% in 2024. The negative margin in the most recent year indicates operational challenges or increased expenses that have eroded operating profitability.
- Net Profit Margin
- The net profit margin follows a similar pattern to the operating margin, decreasing from 43.7% in 2020 to 30.92% in 2021, recovering to 37.2% in 2022, and slightly declining to 36.68% in 2023 before turning negative at -4.86% in 2024. This negative margin reflects a net loss during the latest period, highlighting serious profitability issues.
- Return on Equity (ROE)
- ROE declines steadily from 31.22% in 2020 to -3.26% in 2024. The consistent downward trajectory and eventual negative return indicate diminishing efficiency in generating profit from shareholders' equity and can be a sign of deteriorating overall financial health.
- Return on Assets (ROA)
- ROA decreases similarly, moving from 23.07% in 2020 down to -2.38% in 2024. This trend reveals a declining ability to generate returns from the company's asset base, culminating in a negative return, which suggests that asset utilization has become unprofitable.
In summary, the company's profitability has weakened significantly in recent years. Although gross profit margins remain relatively stable though declining, margins at the operating and net levels have fluctuated markedly and turned negative in the most recent year. Returns on both equity and assets follow a downward trajectory, ending in negative figures by 2024, signaling operational inefficiencies and challenges in sustaining profitable growth.
Return on Sales
Return on Investment
Gross Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Gross profit | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Gross profit margin1 | ||||||
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data reveals consistent growth in both gross profit and revenues over the five-year period. Gross profit increased steadily each year, rising from approximately 5.47 billion US dollars in 2020 to nearly 9.49 billion US dollars in 2024. Similarly, revenues followed an upward trajectory, growing from about 6.21 billion US dollars in 2020 to over 11.02 billion US dollars in 2024.
Despite the upward trends in absolute figures, the gross profit margin shows a gradual decline across the years. The margin decreased from 88.14% in 2020 to 86.11% in 2024, indicating a slight reduction in profitability as a proportion of revenues. This suggests that while the company is generating higher total gross profits, its cost of goods sold may be increasing at a slightly faster rate than revenues.
- Growth in Gross Profit
- A continuous increase every year signifies effective cost management and revenue generation strategies, resulting in higher absolute profit figures.
- Revenue Growth
- Steady expansion of revenues indicates successful sales growth and market demand for the company's products or services over the examined period.
- Gross Profit Margin Decline
- The marginal decrease in gross profit margin percentage points to rising costs or pricing pressures, which may require monitoring to maintain profitability levels.
Overall, the data reflects strong financial performance in terms of growth, albeit with a slight erosion in gross profitability efficiency over the five years under review.
Operating Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Income (loss) from operations | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Operating profit margin1 | ||||||
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Operating Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Operating Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Operating profit margin = 100 × Income (loss) from operations ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
- Revenues
- Revenues showed a consistent upward trend over the analyzed periods, increasing from approximately 6.21 billion US dollars in 2020 to over 11.02 billion US dollars in 2024. The growth was steady year-over-year, reflecting a positive expansion in sales or service income.
- Income (loss) from operations
- Operating income exhibited fluctuations across the years. It began at about 2.86 billion US dollars in 2020, dipped slightly to 2.78 billion in 2021, then sharply increased to 4.31 billion in 2022. A decline followed in 2023 to 3.83 billion, culminating in an operational loss of approximately 0.23 billion US dollars in 2024. This indicates a significant deterioration in operational profitability by the last year.
- Operating profit margin
- The operating profit margin, reflecting the proportion of revenue remaining after covering operating costs, experienced considerable variability. It started at a strong 46.03% in 2020 and decreased to 36.73% in 2021. The margin rebounded to a peak of 48.23% in 2022 but declined again to 38.83% in 2023. By 2024, it turned negative to -2.11%, signaling that operating expenses exceeded revenue, resulting in an operational loss.
- Overall observations
- While revenue growth remained steady and positive throughout the period, operational profitability displayed volatility and a negative turnaround in the final year. The sharp drop into a loss in 2024 despite increased revenues suggests rising costs or other unfavorable factors impacting operational efficiency. This pattern highlights emerging challenges in maintaining profitability despite expanding sales.
Net Profit Margin
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income (loss) | ||||||
Revenues | ||||||
Profitability Ratio | ||||||
Net profit margin1 | ||||||
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Net Profit Margin, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Net Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Net profit margin = 100 × Net income (loss) ÷ Revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- The net income fluctuated notably over the observed periods. From 2020 to 2021, there was a decline from approximately 2.71 billion to 2.34 billion US dollars. This was followed by a significant rise in 2022, reaching around 3.32 billion, and an increase continued into 2023, peaking near 3.62 billion US dollars. However, a sharp reversal occurred in 2024, with the net income turning negative to a loss of approximately 536 million US dollars, indicating a notable financial setback compared to previous years.
- Revenues
- Revenues displayed a consistent upward trend throughout the period. Starting at about 6.21 billion US dollars in 2020, revenues increased steadily each year, reaching approximately 7.57 billion in 2021, 8.93 billion in 2022, 9.87 billion in 2023, and ultimately 11.02 billion US dollars in 2024. This consistent growth reflects expanding business operations or market demand over the five-year span.
- Net Profit Margin
- The net profit margin showed considerable variability. In 2020, the margin was notably high at 43.7%, indicating strong profitability relative to revenues. However, it dropped significantly to 30.92% in 2021, followed by a partial recovery to 37.2% in 2022 and a slight decrease to 36.68% in 2023. In 2024, the margin turned negative to approximately -4.86%, aligning with the net loss reported, which suggests worsening operational efficiency or increased expenses impacting profitability despite rising revenues.
- Overall Analysis
- The data reveals a company experiencing consistent revenue growth over the years, contrasted with volatile profitability. The initial decline in net income and profit margin in 2021 was followed by improvement through 2023. However, 2024 presented a strong divergence where revenues increased, but profitability sharply declined resulting in a net loss. This indicates potential challenges such as increased costs, investment expenditures, or other operational issues affecting net income despite higher sales. The negative net profit margin in the last period warrants further investigation into cost structures and non-operating factors impacting financial performance.
Return on Equity (ROE)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income (loss) | ||||||
Shareholders’ equity | ||||||
Profitability Ratio | ||||||
ROE1 | ||||||
Benchmarks | ||||||
ROE, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
ROE, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROE, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROE = 100 × Net income (loss) ÷ Shareholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- Net income experienced fluctuations over the reported periods. There was a general upward trend from 2020, with net income rising from approximately 2.71 billion US dollars to a peak of about 3.62 billion US dollars by the end of 2023. However, a significant downturn is observed in 2024, with net income declining sharply to a loss of approximately 536 million US dollars. This reversal indicates a substantial negative event or operational challenge impacting profitability in the most recent period.
- Shareholders’ Equity
- Shareholders' equity demonstrated consistent growth throughout the periods under review. Beginning at roughly 8.69 billion US dollars in 2020, equity expanded steadily each year, reaching close to 17.58 billion US dollars by the end of 2023. In 2024, there was a slight decline to approximately 16.41 billion US dollars, but overall equity levels remained significantly higher than at the beginning of the period, reflecting continued capital accumulation or retained earnings growth over the years.
- Return on Equity (ROE)
- ROE showed a decreasing trend despite positive net income growth through 2023. Starting from a high of 31.22% in 2020, ROE dropped to 23.19% in 2021 and remained in the low to mid-20% range through 2022 (23.88%) and 2023 (20.59%). The decline suggests that shareholder equity increased at a faster rate than net income, potentially diluting returns. In 2024, ROE turned negative at -3.26%, corresponding with the net loss reported, indicating that the company did not generate a positive return on its equity investment in that year.
- Summary
- The company experienced strong profitability growth and equity base expansion through 2023. However, the abrupt shift to a net loss and negative equity returns in 2024 marks a significant deviation from prior positive financial performance. This downturn may signal underlying issues affecting earnings quality or operational efficiency that require further investigation. Despite this, the internal capital structure remains substantial, with shareholders’ equity still well above the initial period's level, suggesting resilience in the company’s asset base.
Return on Assets (ROA)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income (loss) | ||||||
Total assets | ||||||
Profitability Ratio | ||||||
ROA1 | ||||||
Benchmarks | ||||||
ROA, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
ROA, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
ROA, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
ROA = 100 × Net income (loss) ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income (Loss)
- The net income exhibited fluctuations over the period analyzed. Starting at approximately 2.7 billion US dollars in 2020, it decreased to about 2.3 billion in 2021. Subsequently, it rebounded significantly to reach 3.3 billion in 2022 and further increased to 3.6 billion in 2023. However, in 2024, there was a sharp reversal with net income turning into a loss of approximately 536 million US dollars. This indicates a notable deterioration in profitability during the last reported year.
- Total Assets
- Total assets showed a consistent upward trend throughout the period. Assets increased from around 11.8 billion US dollars at the end of 2020 to about 13.4 billion in 2021. This growth accelerated in subsequent years, with assets rising to 18.2 billion in 2022 and further expanding to 22.7 billion in 2023. By 2024, total assets slightly decreased to approximately 22.5 billion but remained substantially higher than at the beginning of the period.
- Return on Assets (ROA)
- The ROA demonstrated a declining trend overall. It started at 23.07% in 2020, then fell to 17.44% in 2021. A modest recovery occurred in 2022 with a ROA of 18.3%, yet the ratio declined again to 15.92% in 2023. In 2024, ROA turned negative to -2.38%, reflecting the net loss and indicating reduced efficiency in utilizing the asset base to generate earnings during that year.